ALK

#PRESS: We've just released new data that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis. Read the announcement: rb.gy/epfimh #pharmanews #dkmedier #dkpharma #dkbiz #anaphylaxis #allergy #science

#PRESS: Today at 1.30 p.m. CET, we’ll host a webcast conference call regarding ALK’s full year financial figures for 2025. Join the webcast here: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #annualreport #FYresults

#PRESS: We’ve announced changes to our Executive Leadership Team, meaning that Henriette Mersebach will be leaving ALK as per mutual agreement with our CEO and Board. Find the announcement on our website: shorturl.at/iZ9gh #dkmedier #pharmanews #dkbiz #dkpharma

#PRESS: Our FY & sustainability results are out. Our CEO says: “2025 was a landmark year for ALK, proving the strength of Allergy+ and reflecting our commitment to helping more people across age groups & markets.” shorturl.at/ijqOO #dkmedier #pharmanews #dkbiz #dkpharma

#PRESS: On Friday, 20 Feb, we’ll release our 2025 annual report, incl. our sustainability statement. At 1:30 pm CET, a webcast conference call for investors and analysts will take place. Here’s how to join: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #FYreport

#Press: We’ve received positive recommendation by the CHMP of EMA for our nasal adrenaline spray, 1mg, for the emergency treatment of allergic reactions (anaphylaxis) in children aged 4 years and older (15-30 kg): shorturl.at/Lfp6Q. #pharmanews #dkbiz #dkpharma #dkmedier

It’s #WorldAnaphylaxisDay. Let’s spread awareness of the potentially fatal allergic disease affecting both body & mind. Quick treatment is crucial: In case of signs like facial swelling or trouble breathing, call emergency services and administer adrenaline if available. @EAACI

#PRESS: Today at 1.30 p.m. CET, we will host a webcast conference call regarding our Q3 financial results. Join it via our website here: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

#PRESS: Our Q3 results are out. Our CEO says: “We saw continued positive momentum in the execution of key strategic growth initiatives, most notably in reaching more children with allergy, which is currently ahead of plan." brnw.ch/21wXrwk #dkmedier #pharmanews #dkpharma

#PRESS: On Thursday, 13 November, we will release our Q3 financial results for 2025. A webcast conference call for investors and analysts will take place at 1:30 p.m. CET. Here’s how to join the call: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

Imagine if your child had to miss out on their best friend’s birthday party or a fun family picnic – all because of #allergy. We’re at #PAAM2025 to focus on the importance of advancing care for children worldwide. Thank you @EAACI_HQ for organising the event. #pharmanews

#PRESS: ALK & Gensci partner to expand the AIT market in China. Our CEO says: “We’re very excited about the partnership and look forward to co-operating with GenSci to benefit people with allergy in China.” Read more: shorturl.at/DdUsd #pharmanews #dkpharma #dkmedier #dkbiz

We’re at #GAFA2025 to shed an important light on #foodallergy & #anaphylaxis. Join our symposium today at 13:15 (CEST) on our latest insights and experiences in the treatment of anaphylaxis. Thank you to @GA2LEN_ANACARE for arranging the event. #allergy #science #pharmanews

#PRESS: Real-world evidence supporting clinical effectiveness of nasal adrenaline sprays in US patients experiencing anaphylaxis symptoms during oral food challenge & AIT has been accepted for scientific publication: rb.gy/ygqivy #dkpharma #dkmedier #dkbiz #pharmanews

#PRESS: We expanded our exec leadership team. Our CEO says: “With our strong focus on children with allergy and on anaphylaxis in Europe & North America, elevating these regions into the exec. team will be key for continued execution.” shorturl.at/kIeFq #dkmedier #dkbiz

#PRESS: Today at 1.30 p.m. (CEST), we will host a webcast conference call regarding ALK’s half-year financial results for 2025. Join the webcast: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

#PRESS: Our half-year results are out. Our CEO says: “Q2 marked a step change in ALK’s execution of key strategic growth initiatives. We’re seeing the first contributions to growth and upgraded our FY outlook.” shorturl.at/49peN #dkmedier #pharmanews #dkbiz #intertimreport

#PRESS: Thursday 21 August, we will announce our financial results for the first six months of 2025. At 1.30 p.m. CEST, we will host a webcast conference call for investors and analysts. Join the call: ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

Last call! Apply for the Henning Løwenstein Research #Award before 15 Aug if you're a young #scientist showing excellence in #allergy #research. The winner receives €20,000 & a travel grant to join the award ceremony in Denmark, autumn 2025. brnw.ch/21wUQIW #science #HCP

Attention young #scientists in #allergy #research! Don’t miss your chance to apply for the prestigious Henning Løwenstein Research Award. The deadline for submitting your application is 15 August. Apply via our website: rb.gy/j5f7y7. The winner will receive € 20,000.